Advertisement

Prasterone: A Review in Vulvovaginal Atrophy

  • Young-A HeoEmail author
Adis Drug Evaluation

Abstract

Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a synthetic form of DHEA indicated for the treatment of VVA in postmenopausal women presenting with moderate to severe symptoms in the EU; prasterone is also approved in the USA for the treatment of dyspareunia due to menopause. Approval for the treatment of VVA was based on the results of the phase III ERC-231 and -238 trials in which intravaginal prasterone 6.5 mg/day significantly improved the signs and symptoms of VVA (as assessed by the percentage of parabasal and superficial cells, vaginal pH and the severity of dyspareunia) compared with placebo. The beneficial effects of prasterone were also evident during 52 weeks’ treatment in the phase III ERC-230 safety trial. Prasterone was generally well tolerated, with the most common treatment-emergent adverse event being application site discharge. During 52 weeks of treatment with prasterone, changes in serum concentrations of estrogenic and androgenic metabolites of DHEA increased from baseline but remained within the normal postmenopausal ranges. Thus, intravaginal prasterone is an effective and generally well-tolerated option for the treatment of VVA in postmenopausal women.

Notes

Acknowledgements

During the peer review process, the manufacturer of prasterone was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Young-A Heo is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452–61.CrossRefGoogle Scholar
  2. 2.
    Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health. 2018;10:387–95.CrossRefGoogle Scholar
  3. 3.
    Labrie F. Intravaginal DHEA for the treatment of vulvovaginal atrophy, intracrinology at work. In: Birkhaeuser M, Genazzani A, editors. Pre-menopause, menopause and beyond: volume 5: frontiers in gynecological endocrinology. Cham: Springer International Publishing; 2018. p. 269–84.CrossRefGoogle Scholar
  4. 4.
    Archer DF. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2015;145:139–43.CrossRefGoogle Scholar
  5. 5.
    Labrie F, Belanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–12.CrossRefGoogle Scholar
  6. 6.
    Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220–4.CrossRefGoogle Scholar
  7. 7.
    Archer DF, Labrie F, Montesino M, et al. Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8.CrossRefGoogle Scholar
  8. 8.
    Stuenkel CA, Santen RJ. An introduction to the endocrine society clinical practice guideline on treatment of symptoms of the menopause. Post Reprod Health. 2016;22(1):6–8.CrossRefGoogle Scholar
  9. 9.
    The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.CrossRefGoogle Scholar
  10. 10.
    Neves ECM, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88–92.CrossRefGoogle Scholar
  11. 11.
    Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–34.CrossRefGoogle Scholar
  12. 12.
    European Medicines Agency. Intrarosa: summary of product characteristics. 2019. http://www.ema.europa.eu/. Accessed 20 June 2019.
  13. 13.
    AMAG Pharmaceuticals. Intrarosa (prasterone insert): US prescribing information. 2018. http://www.fda.gov. Accessed 31 May 2019.
  14. 14.
    Labrie F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol. 2015;145:133–8.CrossRefGoogle Scholar
  15. 15.
    Berger L, El-Alfy M, Labrie F. Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol. 2008;109(1–2):67–80.CrossRefGoogle Scholar
  16. 16.
    Pelletier G, Ouellet J, Martel C, et al. Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and innervation. J Sex Med. 2012;9(10):2525–33.CrossRefGoogle Scholar
  17. 17.
    Berger L, El-Alfy M, Martel C, et al. Effects of dehydroepiandrosterone, premarin and acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol. 2005;96(2):201–15.CrossRefGoogle Scholar
  18. 18.
    Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011;14(2):282–8.CrossRefGoogle Scholar
  19. 19.
    Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950–63.CrossRefGoogle Scholar
  20. 20.
    Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56.CrossRefGoogle Scholar
  21. 21.
    Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas. 2015;81(1):46–56.CrossRefGoogle Scholar
  22. 22.
    European Medicines Agency. Intrarosa: European public assessment report. 2017. http://www.ema.europa.eu. Accessed 20 June 2019.
  23. 23.
    Archer D, Labrie F, Martel C, et al. Effect of age, time since menopause and previous hormone therapy on the response to intravaginal 6.5 mg prasterone [abstract no. S-4]. Menopause. 2018;25(12):1485.Google Scholar
  24. 24.
    Labrie F, Archer DF, Martel C, et al. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246–56.CrossRefGoogle Scholar
  25. 25.
    Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401–12.CrossRefGoogle Scholar
  26. 26.
    Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181–90.Google Scholar
  27. 27.
    Labrie F, Montesino M, Archer DF, et al. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner. Climacteric. 2015;18(6):817–25.CrossRefGoogle Scholar
  28. 28.
    Montesino M, Labrie F, Archer DF, et al. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol. 2016;32(3):240–5.CrossRefGoogle Scholar
  29. 29.
    Keating JT, Wang HH. Significance of a diagnosis of atypical squamous cells of undetermined significance for Papanicolaou smears in perimenopausal and postmenopausal women. Cancer. 2001;93(2):100–5.CrossRefGoogle Scholar
  30. 30.
    Martel C, Labrie F, Archer DF, et al. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. J Steroid Biochem Mol Biol. 2016;159:142–53.CrossRefGoogle Scholar
  31. 31.
    Ke Y, Gonthier R, Simard JN, et al. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. Horm Mol Biol Clin Investig. 2015;24(3):117–29.Google Scholar
  32. 32.
    Portman DJ, Labrie F, Archer DF, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22(12):1289–95.CrossRefGoogle Scholar
  33. 33.
    Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–8.CrossRefGoogle Scholar
  34. 34.
    Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA)—results from an international survey. Climacteric. 2012;15(1):36–44.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations